ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.

Nada Hamad,Ian Bilmon,Lynette Chee,Andrea Henden,Anna Johnston,Duncan Purtill,Ashish Bajel,Siok-Keen Tey,David Yeung,Theresa Cole,Clinton Lewis,Jason Butler

Internal medicine journal（2023）

引用 0|浏览1

暂无评分

摘要

This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要